Nasdaq · Healthcare
REGENERON PHARMACEUTICALS, INC. (REGN)
As-reported financials and recent SEC filings for REGENERON PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$14.34B
Net income
$4.50B
Net margin
31.4%
Diluted EPS
$41.48
ROE
14.4%
P/E (TTM)
14.9×
Market cap
$64.18B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Gross profit | — | — | — | — | — |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
13F-HR2026-05-08
View on EDGAR →42026-05-04
View on EDGAR →SCHEDULE 13G2026-04-30
View on EDGAR →10-Q2026-04-29
View on EDGAR →8-K2026-04-29
View on EDGAR →DEFA14A2026-04-24
View on EDGAR →DEF 14A2026-04-24
View on EDGAR →ARS2026-04-24
View on EDGAR →Go deeper on REGN
Search REGENERON PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.